PL1924281T3 - Zmodyfikowany wirus grypy do monitorowania i poprawy skuteczności szczepionki - Google Patents

Zmodyfikowany wirus grypy do monitorowania i poprawy skuteczności szczepionki

Info

Publication number
PL1924281T3
PL1924281T3 PL06813248T PL06813248T PL1924281T3 PL 1924281 T3 PL1924281 T3 PL 1924281T3 PL 06813248 T PL06813248 T PL 06813248T PL 06813248 T PL06813248 T PL 06813248T PL 1924281 T3 PL1924281 T3 PL 1924281T3
Authority
PL
Poland
Prior art keywords
monitoring
influenza virus
modified influenza
vaccine efficiency
improving vaccine
Prior art date
Application number
PL06813248T
Other languages
English (en)
Inventor
Erich Hoffmann
Aleksandr S Lipatov
Robert G Webster
Richard J Webby
Elena A Govorkova
Original Assignee
St Jude Childrens Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital filed Critical St Jude Childrens Res Hospital
Publication of PL1924281T3 publication Critical patent/PL1924281T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
PL06813248T 2005-08-04 2006-07-28 Zmodyfikowany wirus grypy do monitorowania i poprawy skuteczności szczepionki PL1924281T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70580805P 2005-08-04 2005-08-04
PCT/US2006/029575 WO2007019094A2 (en) 2005-08-04 2006-07-28 Modified influenza virus for monitoring and improving vaccine efficiency
EP06813248.9A EP1924281B1 (en) 2005-08-04 2006-07-28 Modified influenza virus for monitoring and improving vaccine efficiency

Publications (1)

Publication Number Publication Date
PL1924281T3 true PL1924281T3 (pl) 2019-10-31

Family

ID=37727844

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06813248T PL1924281T3 (pl) 2005-08-04 2006-07-28 Zmodyfikowany wirus grypy do monitorowania i poprawy skuteczności szczepionki

Country Status (16)

Country Link
US (4) US7871626B2 (pl)
EP (1) EP1924281B1 (pl)
JP (2) JP5395430B2 (pl)
KR (1) KR101334047B1 (pl)
CN (2) CN101283099B (pl)
AU (1) AU2006278696B2 (pl)
BR (1) BRPI0614297A2 (pl)
CA (1) CA2617483C (pl)
ES (1) ES2728791T3 (pl)
HU (1) HUE043952T2 (pl)
PL (1) PL1924281T3 (pl)
RU (3) RU2480480C2 (pl)
SG (1) SG2014007934A (pl)
UA (1) UA94717C2 (pl)
WO (1) WO2007019094A2 (pl)
ZA (1) ZA200800505B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
BRPI0617952A2 (pt) 2005-10-28 2011-08-09 Boehringer Ingelheim Vetmed composição antigênica compreendendo um antìgeno de um patógeno de um animal de uma primeira espécie, bem como uso de vacinas para o tratamento/prevenção da transmissão de patógenos da gripe entre espécies
EP2052340A4 (en) * 2006-08-14 2010-11-17 Massachusetts Inst Technology SYSTEM FOR EXPLORING DATA ON GLYCANES
US8202967B2 (en) * 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
JP5597128B2 (ja) * 2007-05-11 2014-10-01 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド Ｈ５トリインフルエンザの診断および監視に有用なｈ５亜型特異的結合タンパク質
EA017957B1 (ru) * 2007-06-25 2013-04-30 Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд Композиции и способы, ингибирующие грипп
WO2009076778A1 (en) 2007-11-27 2009-06-25 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
CN103990120B (zh) * 2008-04-01 2018-06-05 伊耐特免疫治疗有限公司 抗感染剂及其用途
DK2318530T3 (en) * 2008-07-18 2016-10-03 Medicago Inc Ny epitope to immunization against influenza
ES2614802T3 (es) * 2008-11-28 2017-06-02 Statens Serum Institut Vacunas contra la gripe optimizadas
KR101145720B1 (ko) * 2009-06-23 2012-05-14 한밭대학교 산학협력단 안전성이 뛰어난 인플루엔자 바이러스 백신용 재조합 헤마글루티닌 단백질을 함유하는 생분해성 ｐｌｇａ 미립자의 제조 방법
BRPI1015053A2 (pt) 2009-06-24 2019-07-09 Medicago Inc partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina
JP5745511B2 (ja) * 2009-06-25 2015-07-08 メディミューン，エルエルシー ブタインフルエンザヘマグルチニン変異体
SI3354657T1 (sl) 2009-09-22 2022-05-31 Medicago Inc. Postopek za pripravo iz rastlin izpeljanih beljakovin
CN102095852A (zh) * 2010-11-24 2011-06-15 中国检验检疫科学研究院 一种用于快速检测新型h1n1流感病毒的双抗体夹心法
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
RU2682752C2 (ru) * 2011-09-30 2019-03-21 Медикаго Инк. Повышение выхода вирусоподобных частиц в растениях
AU2013260123A1 (en) 2012-05-10 2014-11-13 Massachusetts Institute Of Technology Agents for influenza neutralization
JP6467672B2 (ja) * 2012-07-17 2019-02-13 メリアル インコーポレイテッド 弱毒ブタインフルエンザワクチンならびにその製造方法および使用方法
KR101315273B1 (ko) * 2012-10-29 2013-10-08 대한민국 강독화된 인플루엔자 바이러스 변이주
CN104491463A (zh) * 2014-11-18 2015-04-08 四川金堂海纳生物医药技术研究所 一种治疗舌溢血(舌衄)的汤剂药物及制备方法
WO2016090297A1 (en) * 2014-12-04 2016-06-09 The New York Stem Cell Foundation Perfusion bioreactor
JOP20190088A1 (ar) * 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
CA3131096A1 (en) 2019-04-05 2020-10-08 Chi-Huey Wong Sialidase-resistant saccharide and method of making and using the same
CA3182526A1 (en) 2020-05-08 2021-11-11 Academia Sinica Chimeric influenza vaccines
WO2022221837A2 (en) 2021-04-12 2022-10-20 Academia Sinica Improved coronavirus vaccine
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
CN117229370B (zh) * 2022-06-08 2024-11-01 中科南京生命健康高等研究院 H5n6禽流感广谱性疫苗的开发及其应用
NZ825394A (en) 2023-04-08 2026-03-27 Rock Biomedical Inc Methods and compositions for dendritic cell targeting nano-delivery
CA3268566A1 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES
CN121175414A (zh) 2023-05-17 2025-12-19 磐石医药生技股份有限公司 Mgat1缺乏细胞及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
ES2593082T3 (es) * 2003-05-28 2016-12-05 Wisconsin Alumni Research Foundation Virus de la gripe recombinantes a título elevado para vacunas y terapia génica
CN1261564C (zh) * 2003-12-02 2006-06-28 中国农业科学院哈尔滨兽医研究所 人工重组的流感病毒及其应用
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency

Also Published As

Publication number Publication date
RU2008107875A (ru) 2009-09-10
US20110104202A1 (en) 2011-05-05
RU2480480C2 (ru) 2013-04-27
AU2006278696A8 (en) 2008-03-06
JP2009502197A (ja) 2009-01-29
EP1924281B1 (en) 2019-05-08
ZA200800505B (en) 2008-12-31
US9499850B2 (en) 2016-11-22
US7871626B2 (en) 2011-01-18
WO2007019094A2 (en) 2007-02-15
UA94717C2 (ru) 2011-06-10
CN101283099B (zh) 2013-03-27
WO2007019094A3 (en) 2007-07-12
RU2013101020A (ru) 2014-07-20
CN103172710B (zh) 2016-08-17
JP2014003982A (ja) 2014-01-16
BRPI0614297A2 (pt) 2011-03-22
CA2617483C (en) 2016-09-27
EP1924281A2 (en) 2008-05-28
CA2617483A1 (en) 2007-02-15
CN103172710A (zh) 2013-06-26
KR101334047B1 (ko) 2013-11-29
KR20080042864A (ko) 2008-05-15
HUE043952T2 (hu) 2019-09-30
ES2728791T3 (es) 2019-10-28
EP1924281A4 (en) 2014-01-01
RU2552213C2 (ru) 2015-06-10
SG2014007934A (en) 2014-04-28
RU2011103648A (ru) 2012-08-10
JP5395430B2 (ja) 2014-01-22
CN101283099A (zh) 2008-10-08
AU2006278696A1 (en) 2007-02-15
JP5745584B2 (ja) 2015-07-08
US8293247B2 (en) 2012-10-23
US20130017216A1 (en) 2013-01-17
AU2006278696B2 (en) 2012-03-15
US20070031453A1 (en) 2007-02-08
US8574592B2 (en) 2013-11-05
RU2420535C2 (ru) 2011-06-10
US20140030702A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
ZA200800505B (en) Modified influenza virus for monitoring and improving vaccine efficiency
PL2281831T3 (pl) Szczepionka przeciw wirusowi ospy wietrznej i półpaśca
ZA200802892B (en) Vaccines and methods to treat canine influenza
SG2014012868A (en) Functional influenza virus like particles (vlps)
IL186611A0 (en) Vaccine against pandemic strains of influenza viruses
IL189329A0 (en) Vaccination against dengue virus infection
IL218203A0 (en) Defective influenza virus particle
EP2091960A4 (en) PEPTIDE VACCINE AGAINST INFLUENZA VIRUS
IL186710A (en) Influenza A virus is isolated from dogs, a drug and vaccine that include it and its use
IL196024A0 (en) Influenza vaccine
EP2170382A4 (en) ATTENUATED INFLUENZA VIRUS AND LIVE VACCINE CONTAINING IT
AP2008004625A0 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
ZA200809056B (en) Influenza virus vaccine
BRPI0821034A2 (pt) Vírus influenza modificado
ZA200905952B (en) Lyophilized preparation comprising influenza vaccine,and method for preparation thereof
PL2358386T3 (pl) Zoptymalizowane szczepionki na grypę
SI2043682T1 (sl) Influenčno cepivo
PL1942933T3 (pl) Szczepionki przeciw grypie psów
GB0523347D0 (en) Influenza a virus detection method and kit therefor
SI1951299T1 (sl) Cepiva proti influenci, ki vkljuäśujejo kombinacije adjuvantov iz delcev in imunopotenciatorjev
EP1871786A4 (en) PEPTIDE VACCINE AGAINST THE GRIPPEVIRUS
GB0600081D0 (en) Chicken virus vaccine and diagnostic
ZA200802176B (en) Vaccination against dengue virus infection
ZA200703793B (en) Defective influenza virus particles
ZA200900062B (en) Influenza vaccine